Cancer Supportive Care Drugs: A Leading Driver Behind Rising Cancer Survival Rates Drive Growth In The Cancer Supportive Care Drugs Market Market Expansion in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Cancer Supportive Care Drugs Industry Market Size Be by 2025?
The market size for cancer supportive care drugs has seen a consistent increase over the past years. The market, which is expected to be at $20.83 billion in 2024, is predicted to escalate to $21.54 billion by 2025, exhibiting a compound annual growth rate (CAGR) of 3.4%. The substantial growth observed in the preceding years is due to factors such as the aging population, the rise in chemotherapy incidents, the mounting demand for antiemetics, the growing inclination towards online pharmacies and drug stores, increased awareness about supportive care, the rise in personalized medicine, and a greater focus on palliative care.

What's the Long-Term Growth Forecast for the Cancer Supportive Care Drugs Market Size Through 2029?
The market for cancer supportive care drugs is projected to steadily proliferate in the coming years, reaching a value of $25.07 billion in 2029 with a compound annual growth rate (CAGR) of 3.9%. The anticipated rise during this projected period can be ascribed to an increased awareness of the negative impacts of cancer treatments, a growing incidence of breast cancer among women, the presence of specific medication regimens, the burgeoning demand for online medical consultations, an enhanced distribution network in the pharmaceutical sector, and a rising number of cancer survivors. Key market trends over this projected period include advancements in targeted treatment methods, the incorporation of biobehavioral interventions, execution of survivorship care programs, the integration of nutritional assistance, improvement in pain management techniques, and the use of symptom monitoring platforms.

View the full report here:
https://www.thebusinessresearchcompany.com/report/cancer-supportive-care-drugs-global-market-report

What Are the Key Growth Drivers Fueling the Cancer Supportive Care Drugs Market Expansion?
The anticipated growth of the cancer supportive care drugs market is linked to the increased survival rate among cancer patients. The term cancer survival rate pertains to the proportion of patients who survive a particular form of cancer for a defined period, generally five years, post-diagnosis. The driving factors behind survival rates for cancer patients mainly include early detection, advancements in treatment, access to high-quality healthcare, the patient's overall health condition, the kind of cancer and its stage, and socioeconomic elements. By managing side effects like pain, nausea, and anemia, cancer supportive care drugs play a significant role in enhancing the survival rates of patients. They help patients better endure their treatments and complete the entire therapy course, leading to improved outcomes. For example, the US-based government agency National Cancer Institute predicted in January 2022 that the number of cancer survivors would increase by 24.4% in the coming ten years, totaling 22.5 million by 2032. Hence, the amplified survival rate of cancer patients is bolstering the cancer supportive care drugs market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15749&type=smp

What Are the Key Trends Driving Cancer Supportive Care Drugs Market Growth?
Prominent firms in the cancer support care drugs market are working on combination therapies to tackle the intricacies and difficulties of cancer treatment. These therapies involve the deliberate use of multiple therapeutic agents to target varying elements of cancer growth and survival, with the goal of achieving longer-lasting and more extensive results than monotherapy. For example, in 2023, the US-based pharmaceutical company, Merck, was granted approval by the Food and Drug Administration for KEYTRUDA, an anti-PD-1 therapy, combined with gemcitabine and cisplatin, for treating patients with locally advanced unresectable or metastatic biliary tract cancer (BTC). The mixture therapy demonstrated encouraging outcomes in extending overall survival and offering a novel treatment alternative for patients suffering from this demanding disease.

How Is the Cancer Supportive Care Drugs Market Segmented?
The cancer supportive care drugs market covered in this report is segmented -

1) By Type: Erythropoiesis Stimulating Agents, Granulocyte Colony Stimulating Factors, Antiemetics, Bisphosphonates, Opioids, Nonsteroidal Anti Inflammatory Drugs, Other Types
2) By Application: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer, Stomach Cancer, Other Applications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics, Other Channels

Subsegments:
1) By Erythropoiesis Stimulating Agents: Epoetin Alfa, Darbepoetin Alfa, Methoxy Polyethylene Glycol-Epoetin Beta
2) By Granulocyte Colony Stimulating Factors: Filgrastim, Pegfilgrastim, Lenograstim
3) By Antiemetics: 5-HT3 Receptor Antagonists, NK1 Receptor Antagonists, Corticosteroids
4) By Bisphosphonates: Zoledronic Acid, Pamidronate, Ibandronate
5) By Opioids: Morphine, Fentanyl, Oxycodone
6) By Nonsteroidal Anti Inflammatory Drugs (NSAIDs): Ibuprofen, Diclofenac, Celecoxib
7) By Other Types: Steroids, Anxiolytics, Appetite Stimulants

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=15749&type=smp

Which Companies Are Leading the Charge in Cancer Supportive Care Drugs Market Innovation?
Major companies operating in the cancer supportive care drugs market are Pfizer Inc., Johnson & Johnson, Merck, AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, F Hoffmann-La Roche Ltd., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Baxter International Inc., Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Eisai Co. Ltd., Incyte Corporation, Exelixis Inc., Fagron Group, Heron Therapeutics Inc., Athenex Inc., Acrotech Biopharma LLC

Which Regions Are Leading the Global Cancer Supportive Care Drugs Market in Revenue?
North America was the largest region in the cancer supportive care drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer supportive care drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15749

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.